ArticleFrontiers in pediatrics2026
The pathogenic role of high-titer anti-Ro52 antibodies in neonatal lupus erythematosus: insights from a 9 case series.
Article in Frontiers in pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Neonatal Lupus Erythematosus (NLE) is a rare acquired autoimmune disease caused by the transplacental transfer of maternal anti-Ro/SSA and anti-La/SSB antibodies. Despite the high prevalence of these antibodies in mothers with Systemic Lupus Erythematosus (SLE) and Sjögren's Syndrome (SS), the clinical manifestations in neonates are highly heterogeneous, ranging from transient cutaneous lesions to life-threatening congenital heart block (CHB). Methods: This study analyzed a case series of nine mother-infant pairs diagnosed with NLE. We integrated clinical outcomes, maternal serological profiles (including quantitative anti-Ro52, Ro60, and La titers), and pharmacological interventions to explore the determinants of disease severity and organ-specific manifestations. Results: Among the nine mothers, six (66.7%) had Sjögren's syndrome and three (33.3%) had systemic lupus erythematosus, including two with secondary antiphospholipid syndrome. Notably, 88.9% of mothers were diagnosed with autoimmune disease during or after the affected pregnancy. All mothers demonstrated antinuclear antibody positivity and were uniformly positive for anti-SSA/Ro, anti-SSB/La, and anti-Ro52 antibodies. Cardiac involvement occurred in three pregnancies, including recurrent complete CHB leading to pregnancy termination in one mother. One fetus with second-degree atrioventricular block received prompt dexamethasone therapy and achieved successful reversal of conduction abnormalities. Cutaneous manifestations were observed in five neonates, while hematologic involvement, primarily thrombocytopenia and anemia, occurred in four cases. Maternal hypocomplementemia and elevated inflammatory markers appeared to be associated with more severe fetal outcomes. Conclusion: All nine mothers (100%) tested positive for high-titer anti-Ro52 antibodies, a finding consistent with the proposed role of anti-Ro52 as a risk biomarker for NLE. Intensive fetal echocardiographic surveillance between 16 and 26 weeks of gestation is vital to capture the critical window of low-degree conduction block, where synergistic immunomodulation with dexamethasone can reverse fetal heart block prior to irreversible nodal fibrosis. NLE serves as an early warning sign of occult maternal autoimmune disease, requiring long-term maternal follow-up.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.